Investigational New Drug Application Filed for CFI-400945
Investigators from Princess Margaret Cancer Centre in Toronto and the University of California, Los Angeles, have submitted an Investigational New Drug (IND) application for CFI-400945, a novel drug candidate targeting the enzyme PLK4, which plays a crucial role in cell division.
The news was announced at a press briefing by Tak Mak, MD, OC, PhD, DSc (Hon), FRSC, FRS, Director of The Campbell Family Institute for Breast Cancer Research at Princess Margaret Cancer Centre, and Dennis J. Slamon, MD, PhD, Director of Clinical/Translational Research at UCLA’s Jonsson Comprehensive Cancer Center.
In lab studies, the agent has been shown to effectively inhibit the growth of human breast and ovarian cancers, as well as colorectal, glioblastoma, lung, melanoma, pancreatic, and prostate cancers.
The new drug will enter clinical trials in the months ahead, upon completion of the FDA’s review of the IND application.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
